Anna Brandt

Erlangen, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Toward precision immunotherapy in recurrent/metastatic head and neck squamous cell carcinoma: lessons from the FOCUS trial.

Toward precision immunotherapy in recurrent/metastatic head and neck squamous cell carcinoma: lessons from the FOCUS trial.

Journal: Translational cancer research
Published: April 16, 2026

Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer.

Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer.

Journal: NPJ precision oncology
Published: December 09, 2024

UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial.

UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial.

Journal: Med (New York, N.Y.)
Published: October 30, 2024

Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHD.

Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHD.

Journal: Blood
Published: October 15, 2024

Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial.

Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial.

Journal: Frontiers in oncology
Published: August 25, 2023

Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.

Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.

Journal: Cancers
Published: March 01, 2023

Clinical Predictors of Neurogenic Lower Urinary Tract Dysfunction in Persons with Multiple Sclerosis.

Clinical Predictors of Neurogenic Lower Urinary Tract Dysfunction in Persons with Multiple Sclerosis.

Journal: Diagnostics (Basel, Switzerland)
Published: November 30, 2021

Current aspects of neurogenic dysfunctions of the lower urinary tract in multiple sclerosis

Current aspects of neurogenic dysfunctions of the lower urinary tract in multiple sclerosis

Journal: Der Nervenarzt
Published: December 10, 2020

Neurourological assessment in people with multiple sclerosis (MS): a new evaluated algorithm.

Neurourological assessment in people with multiple sclerosis (MS): a new evaluated algorithm.

Journal: Multiple sclerosis and related disorders
Published: April 03, 2020

A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells.

A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells.

Journal: Leukemia & lymphoma
Published: July 24, 2018

Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.

Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.

Journal: Haematologica
Published: May 20, 2017

Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA.

Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA.

Journal: Haematologica
Published: November 30, 2016
Showing 1-12 of 14

Last Updated: 09/26/2026